3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Alfredo Arvide of Slalom Consulting, Allison Post of the Texas Heart Institute, and Jeff Price of Pronto Pay. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — tech consulting, health care, and fintech — recently making headlines in Houston innovation.

Alfredo Arvide, senior principal within product engineering at Slalom Consulting

Should you launch an app? Or just a web page? This consultant weighs in with his advice. Photo courtesy of Slalom

Tech founders have a lot of decisions to make, and Alfredo Arvide of Slalom Consulting wrote a guest column for InnovationMap to help advise on a big one.

"One of the biggest decisions you'll have to make as an entrepreneur is whether you should host your product or service on the web, via an app, or through a webapp," he writes. "Product development has a million intricacies that will dictate – and sometimes demand – a specific route to market." Read more.

Allison Post, manager of innovation partnerships at the Texas Heart Institute

Allison Post joins the Houston Innovators Podcast to share what she's focused on in cardiac innovation. Photo courtesy of THI

In a perfect world, Houston's health care institutions work collaboratively on innovative health care solutions and the city soars as a major hub for life science innovation. That perfect world is Allison Post's goal. As Texas Heart Institute's manager of innovation partnerships, she is in charge of supporting THI innovators and connecting the institute with the rest of the city.

"I only see just phenomenal things for Houston, and what I really want is for the Texas Medical Center to become even more interconnected. We've got to be able to transfer ideas and thoughts and intentions seamlessly between these institutions and right now there are a lot of barriers," Post says. "And I really think Texas Heart is hopefully going to serve as an example of how to take down those barriers." Read more and stream the episode.

Jeff Price, founder and CEO of Pronto Pay

This Houston startup has an app for helping employees get a portion of their paychecks before payday. Photo via Pexels

So much of the country lives paycheck to paycheck, and Jeff Price saw a business opportunity to help out employees who need an advance on their wages. He founded Pronto Pay in the first quarter of 2021. The software aims to connect hourly works with transparent access to wages earned before pay day without disrupting the employers' books.

"When you think about it, payroll hasn't changed in nearly two centuries. As far as we can remember, you get paid weekly or bi-weekly. And that's precisely the point we're trying to solve," Price says. Read more.

This Houston startup has an app for helping employees get a portion of their paychecks before payday. Photo via Pexels

Houston-based software startup aims to connect workers with wages in real time

there's an app for that

Could you incur an unexpected $400 expense if it hit your bank account today? According to Jeff Price, founder and CEO of Houston-based Pronto Pay, many hourly workers could not. He's set out to change that.

A recent graduate from Rice University's Jones Graduate School of Business, Price founded Pronto Pay in the first quarter of 2021. The software aims to connect hourly works with transparent access to wages earned before pay day without disrupting the employers' books. Currently the company has seven staff members, is actively hiring and is looking to expand outside of Houston soon.

Pronto Pay partners with the employers to seamlessly build out connections with their time and attendance system and payroll processor. After the company signs up, ProntoPay automatically creates an account for each employee, which allows them to view their accrued wages and withdraw their earnings instantly from the app or next-day for automated clearing house payments — all via the Pronto Pay App. When an employee wishes to withdraw funds prior to their normal pay cycle, Pronto Pay applies a small fixed fee — $2.99 — for completing the transaction. .

Come pay day, the employer's system will automatically balance the difference and route the withdrawn money back to Pronto Pay. As Price describes it, Pronto Pay aims to compete "directly with (while severely undercutting the price of) payday and other predatory lenders."

The idea was born out of a series of simple questions Price started to ask himself when he envisioned what his newborn son's first job would be earlier this year.

"My wife and I were having our son and it challenged me to ask questions like, 'Hey, why do we get paid bi-weekly? If I can Venmo 100 bucks in real time, why can't a company do that?'" Price recalls.

Apart from the impact of advanced pay, Price envisions that earned wages access will improve workplace culture and retention, too. Pronto Pay has already on-boarded users in the local staffing and warehousing markets, in the janitorial and security guard fields, and at call centers. As Price describes, Pronto Pay's clients "typically have a lot of hourly employees that struggle with employee retention and keeping folks at the same job for longer than three to 12 months."

"We're hoping that we can permanently change that employee-employer relationship," he adds. "And help those employees."

Jeff Price is the founder and CEO of Pronto Pay.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME